
Sign up to save your podcasts
Or


This week on Biotech Nation, Paul Hastings, CEO of Nkarta and former chair of BIO—the Biotechnology Innovation Organization—discusses the impact of cuts to research funding and stepping away from recommending vaccines—what this means for you and the biotech industry.
By Moira Gunn4.1
2929 ratings
This week on Biotech Nation, Paul Hastings, CEO of Nkarta and former chair of BIO—the Biotechnology Innovation Organization—discusses the impact of cuts to research funding and stepping away from recommending vaccines—what this means for you and the biotech industry.

21,967 Listeners

43,944 Listeners

32,101 Listeners

30,693 Listeners

43,701 Listeners

708 Listeners

6,386 Listeners

30,226 Listeners

124 Listeners

323 Listeners

9,957 Listeners

33 Listeners

19 Listeners

48 Listeners

139 Listeners